RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerT cell clonality assays are of increasing interest in the field of T cell immunotherapy. In this context, the identification of a tumour-specific T cell clone, typified by a specific T cell clonotype, can be critical to the success and monitoring of therapy.
It is conceivable that future clinical need for T cell clonality assessment will be dominated by immunotherapeutic indications, rather than just diagnostic ones since clonality forms reliable proof that two seemingly distinct T cell lymphoproliferative disorders are derived from the same malignant clonal population, like in breast and pancreatic cancer, and to provide molecular genetic evidence of a clonal T cell infiltrate, as treatment with ONCYs pelareorep is demonstrating.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868531/